The Veterinary record · 2026
Effect of flunixin meglumine on the pharmacokinetics of enrofloxacin and marbofloxacin in preweaning calves.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pizarro Natalia Urzúa, Messina María J, Prieto Guillermo, Post Carlos Lüders, Errecalde Carlos
Аннотация
BACKGROUND: Bovine respiratory disease is a major cause of illness in dairy calves. Fluoroquinolones such as enrofloxacin and marbofloxacin are commonly co-administered with flunixin meglumine, yet NSAID-related pharmacokinetic interactions in preweaning calves remain poorly defined. This study evaluated flunixin's effects on these drugs' pharmacokinetics and pharmacokinetic/pharmacodynamic (PK/PD) indices against key bovine respiratory pathogens of clinical relevance.
METHODS: Ten healthy Holando Argentino calves (20-30 days old) received enrofloxacin (5 mg/kg intramuscularly) or marbofloxacin (6 mg/kg intramuscularly). After a 15-day washout period, calves received the same antimicrobial co-administered with flunixin meglumine (2.2 mg/kg intramuscularly). The plasma concentrations of the drugs in the first 24 hours after administration were measured using validated high-performance liquid chromatography, and non-compartmental analysis was performed to derive pharmacokinetic parameters. PK/PD indices were also calculated.
RESULTS: Flunixin meglumine significantly prolonged the elimination half-life of both antimicrobials without modifying the area under the concentration-time curve from 0 to 24 hours. It also reduced the biotransformation of enrofloxacin to ciprofloxacin. PK/PD targets were achieved for Pasteurella multocida and Histophilus somni but not for Mannheimia haemolytica or Mycoplasma bovis.
LIMITATIONS: The study was limited by the use of clinically healthy calves only, the small sample size, reliance on published minimum inhibitory concentration values and plasma-based PK/PD analysis.
CONCLUSION: Flunixin prolongs elimination of enrofloxacin and marbofloxacin without compromising estimated efficacy, although optimisation may be required for some bovine respiratory disease pathogens.
METHODS: Ten healthy Holando Argentino calves (20-30 days old) received enrofloxacin (5 mg/kg intramuscularly) or marbofloxacin (6 mg/kg intramuscularly). After a 15-day washout period, calves received the same antimicrobial co-administered with flunixin meglumine (2.2 mg/kg intramuscularly). The plasma concentrations of the drugs in the first 24 hours after administration were measured using validated high-performance liquid chromatography, and non-compartmental analysis was performed to derive pharmacokinetic parameters. PK/PD indices were also calculated.
RESULTS: Flunixin meglumine significantly prolonged the elimination half-life of both antimicrobials without modifying the area under the concentration-time curve from 0 to 24 hours. It also reduced the biotransformation of enrofloxacin to ciprofloxacin. PK/PD targets were achieved for Pasteurella multocida and Histophilus somni but not for Mannheimia haemolytica or Mycoplasma bovis.
LIMITATIONS: The study was limited by the use of clinically healthy calves only, the small sample size, reliance on published minimum inhibitory concentration values and plasma-based PK/PD analysis.
CONCLUSION: Flunixin prolongs elimination of enrofloxacin and marbofloxacin without compromising estimated efficacy, although optimisation may be required for some bovine respiratory disease pathogens.